Inclusion Criteria:

- Patient must be 18 years or older with confirmed diagnosis of breast adenocarcinoma,
colorectal carcinoma or non-small cell lung cancer

- Patients must have relapsed or refractory disease following at least one
chemotherapeutic treatment regimen.

- Has a measurable, positron emission tomography (PET) assessable lesion

- Adequate blood, liver, bone marrow and kidney functions

- Has not received any chemotherapy for at least 4 weeks prior to entry in this study

- Agrees to take adequate measures to prevent pregnancy.

Exclusion Criteria:

- Patient has had prior treatment with histone deacetylase (HDAC) inhibitor.

- Patient has had treatment with investigational agents within the last 30 days.

- Patient has active infection or had intravenous (IV) antibiotic, antiviral, or
antifungal medications within 2 weeks of the start of study drugs.

- Patient has HIV, hepatitis B or hepatitis C infection.

- Patient is pregnant or lactating.

- Patient has allergy to any component of the study drug.